BioGeometry
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 1
- BioGeometry links AI models with automated drug-discovery experiments
BioGeometry has developed what it calls a “self-evolving microscopic world model,” connecting molecular design, cell-response modeling and automated experiments so results can feed back into the system. The report says the company’s GeoFlow V3 achieved a nearly 20% average hit rate for lead molecules across more than 20 targets and compressed lead-discovery cycles to within three weeks; in a project for a European pharmaceutical company, it reportedly identified multiple molecules meeting multiple requirements in one iteration and shortened delivery by more than 50%. GeoCell models transcriptional responses under different perturbations for target discovery, indication selection and patient stratification. BioGeometry was also reported to have completed an A+ financing round, bringing cumulative Series A funding above $100 million. Most performance figures came from the company, while the financing was not independently confirmed in the report.
MIT科技评论中文 · 🔥 0
Experience and discussion from the community
Share my BioGeometry experienceAsk about BioGeometry
Nobody has shared their experience with BioGeometry yet.